{
    "xml": "<topic id=\"PHP5086\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/oxybutynin-hydrochloride\" basename=\"oxybutynin-hydrochloride\" title=\"OXYBUTYNIN HYDROCHLORIDE\">\n<title>OXYBUTYNIN HYDROCHLORIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_356\" namespace=\"/interactions/list-of-drug-interactions/antimuscarinics/oxybutynin\">Oxybutynin</xref>\n</p>\n<data name=\"vtmid\">35768004</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_567112641\" title=\"Antimuscarinics\">Antimuscarinics</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34659\" title=\"ANTIMUSCARINICS (SYSTEMIC)\" namespace=\"/drug-classes/antimuscarinics-systemic\">ANTIMUSCARINICS (SYSTEMIC)</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP43254\" outputclass=\"indicationsAndDose\" rev=\"1.59\" parent=\"/drugs/oxybutynin-hydrochloride\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Urinary frequency</p>\n<p outputclass=\"therapeuticIndication\">Urinary urgency</p>\n<p outputclass=\"therapeuticIndication\">Urinary incontinence</p>\n<p outputclass=\"therapeuticIndication\">Neurogenic bladder instability</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">Initially by mouth using immediate-release medicines</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 5&#8211;11 years</p>\n<p>Initially 2.5&#8211;3&#8239;mg twice daily, (by mouth using immediate-release medicines) increased to 5&#8239;mg 2&#8211;3 times a day.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>Initially 5&#8239;mg 2&#8211;3 times a day, (by mouth) increased if necessary up to 5&#8239;mg 4 times a day.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 5&#8239;mg 2&#8211;3 times a day, (by mouth) increased if necessary up to 5&#8239;mg 4 times a day.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Elderly</p>\n<p>Initially 2.5&#8211;3&#8239;mg twice daily, (by mouth using immediate-release medicines) increased if tolerated to 5&#8239;mg twice daily, adjusted according to response.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">Initially by mouth using modified-release tablets</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 5&#8211;17 years</p>\n<p>Initially 5&#8239;mg once daily, (by mouth) adjusted in steps of 5&#8239;mg every 1&#8239;week, adjusted according to response; maximum 15&#8239;mg per day.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 5&#8239;mg once daily, (by mouth) increased in steps of 5&#8239;mg every 1&#8239;week, adjusted according to response; maximum 20&#8239;mg per day.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By transdermal application using patches</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Apply 1&#8239;patch twice weekly, patch is to be applied to clean, dry unbroken skin on abdomen, hip or buttock. Patch should be removed every 3-4 days and site replacement patch on a different area. The same area should be avoided for 7 days.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Nocturnal enuresis associated with overactive bladder</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth using immediate-release medicines</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 5&#8211;17 years</p>\n<p>2.5&#8211;3&#8239;mg twice daily, increased to 5&#8239;mg 2&#8211;3 times a day, last dose to be taken before bedtime.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">Initially by mouth using modified-release tablets</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 5&#8211;17 years</p>\n<p>Initially 5&#8239;mg once daily, (by mouth) adjusted in steps of 5&#8239;mg every 1&#8239;week, adjusted according to response; maximum 15&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseEquivalence\">\n<title>Dose equivalence and conversion</title>\n<p>Patients taking immediate-release oxybutynin may be transferred to the nearest equivalent daily dose of <i>Lyrinel <tm tmtype=\"reg\"/> XL</i>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43116\" outputclass=\"unlicensedUse\" rev=\"1.11\" parent=\"/drugs/oxybutynin-hydrochloride\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">In children</p>\n<p>Not licensed for use in children under 5 years.</p>\n<p>Intravesical instillation not licensed for use in children.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43345\" outputclass=\"cautions\" rev=\"1.26\" parent=\"/drugs/oxybutynin-hydrochloride\">\n<title>Cautions</title>\n<body>\r\n<section outputclass=\"cautions\">\r\n<p>\r\n<ph outputclass=\"caution\">\r\n<xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>\r\n</ph>\r\n</p>\r\n </section>\r\n\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP43154\" outputclass=\"sideEffects\" rev=\"1.19\" parent=\"/drugs/oxybutynin-hydrochloride\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<title>General side-effects:</title>\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Anorexia</ph>; <ph outputclass=\"sideEffect\">facial flushing</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Night terrors</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Cognitive impairment</ph> (in adults)</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"specificSideEffects\">\n<title>Specific side-effects:</title>\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<sectiondiv outputclass=\"sideEffectsWithRoutes\">\n<p outputclass=\"title\">With transdermal use</p>\n<p>\n<ph outputclass=\"sideEffect\">application site reactions with <i>patches</i>\n</ph> (in adults)</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43223\" outputclass=\"pregnancy\" parent=\"/drugs/oxybutynin-hydrochloride\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturers advise avoid unless essential&#8212;toxicity in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43359\" outputclass=\"breastFeeding\" parent=\"/drugs/oxybutynin-hydrochloride\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturers advise avoid&#8212;present in milk in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43278\" outputclass=\"hepaticImpairment\" parent=\"/drugs/oxybutynin-hydrochloride\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43196\" outputclass=\"renalImpairment\" parent=\"/drugs/oxybutynin-hydrochloride\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43376\" outputclass=\"directionsForAdministration\" rev=\"1.13\" parent=\"/drugs/oxybutynin-hydrochloride\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">transdermal</ph> use in adults</p>\n<p>Apply patches to clean, dry, unbroken skin on abdomen, hip or buttock, remove after every 3&#8211;4 days and site replacement patch on a different area (avoid using same area for 7 days).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59536\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.9\" parent=\"/drugs/oxybutynin-hydrochloride\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">In adults</p>\n<p>The need for continuing therapy for urinary incontinence should be reviewed every 4&#8211;6 weeks until symptoms stabilise, and then every 6&#8211;12 months.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">In children</p>\n<p>The need for therapy for urinary indications should be reviewed soon after it has been commenced and then at regular intervals; a response usually occurs within 6 months but may take longer.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">In children</p>\n<p>Intravesical instillation may be available from 'special-order' manufacturers or specialist importing companies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43213\" outputclass=\"patientAndCarerAdvice\" rev=\"1.24\" parent=\"/drugs/oxybutynin-hydrochloride\">\n<title>Patient and carer advice</title>\n<body>\r\n\r\n\r\n<section outputclass=\"patientResources\">\r\n<sectiondiv>\r\n<p outputclass=\"specificity\">In children</p>\r\n<p outputclass=\"title\">Medicines for Children leaflet: Oxybutynin for daytime urinary symptoms</p>\r\n<p>\n<xref format=\"html\" href=\"http://www.medicinesforchildren.org.uk/oxybutynin-for-daytime-urinary-symptoms\">www.medicinesforchildren.org.uk/oxybutynin-for-daytime-urinary-symptoms</xref>\n</p>\n</sectiondiv>\n</section>\r\n<section outputclass=\"generalPatientAdvice\">\r\n<sectiondiv>\r\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">transdermal</ph> use in adults</p>\r\n<p>Patients or carers should be given advice on how to administer oxybutynin transdermal patches.</p>\n</sectiondiv>\n</section>\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP43071\" outputclass=\"nationalFunding\" rev=\"1.15\" parent=\"/drugs/oxybutynin-hydrochloride\">\n<title>National funding/access decisions</title>\n<body>\n<section>\n<sectiondiv outputclass=\"smcDecisions\">\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\n<sectiondiv outputclass=\"smcDecision\">\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">transdermal</ph> use in adults</p>\n<p>The <i>Scottish Medicines Consortium</i> has advised (July 2005) that <i>Kentera</i>\n<tm tmtype=\"reg\"/> should be restricted for use in patients who benefit from oral oxybutynin but cannot tolerate its side-effects.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP5086-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/oxybutynin-hydrochloride\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral suspension, oral solution, bladder irrigation</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77041\" title=\"Tablet\" namespace=\"/drugs/oxybutynin-hydrochloride/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77048\" title=\"Modified-release tablet\" namespace=\"/drugs/oxybutynin-hydrochloride/modified-release-tablet\">Modified-release tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77063\" title=\"Oral solution\" namespace=\"/drugs/oxybutynin-hydrochloride/oral-solution\">Oral solution</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77056\" title=\"Transdermal patch\" namespace=\"/drugs/oxybutynin-hydrochloride/transdermal-patch\">Transdermal patch</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78573\" namespace=\"/treatment-summaries/urinary-frequency-enuresis-and-incontinence\" title=\"Urinary frequency, enuresis and incontinence\" count=\"4\" rel=\"backlink\">Urinary frequency, enuresis and incontinence</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_356\" namespace=\"/interactions/list-of-drug-interactions/antimuscarinics/oxybutynin\" title=\"Oxybutynin\" count=\"1\" rel=\"link\">Oxybutynin</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34659\" namespace=\"/drug-classes/antimuscarinics-systemic\" title=\"ANTIMUSCARINICS (SYSTEMIC)\" count=\"1\" rel=\"link\">ANTIMUSCARINICS (SYSTEMIC)</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78608\" namespace=\"/treatment-summaries/acute-porphyrias\" title=\"Acute porphyrias\" count=\"1\" rel=\"link\">Acute porphyrias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77041\" namespace=\"/drugs/oxybutynin-hydrochloride/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77048\" namespace=\"/drugs/oxybutynin-hydrochloride/modified-release-tablet\" title=\"Modified-release tablet\" count=\"1\" rel=\"link\">Modified-release tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77063\" namespace=\"/drugs/oxybutynin-hydrochloride/oral-solution\" title=\"Oral solution\" count=\"1\" rel=\"link\">Oral solution</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77056\" namespace=\"/drugs/oxybutynin-hydrochloride/transdermal-patch\" title=\"Transdermal patch\" count=\"1\" rel=\"link\">Transdermal patch</xref>\n</links>\n</topic>",
    "id": "PHP5086",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/oxybutynin-hydrochloride",
    "basename": "oxybutynin-hydrochloride",
    "title": "OXYBUTYNIN HYDROCHLORIDE",
    "interactants": [
        {
            "id": "bnf_int_356",
            "label": "Oxybutynin"
        }
    ],
    "vtmid": "35768004",
    "drugClassification": [
        "Antimuscarinics"
    ],
    "inheritsFromClass": [
        "ANTIMUSCARINICS (SYSTEMIC)"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Urinary frequency",
                        "html": "Urinary frequency"
                    },
                    {
                        "textContent": "Urinary urgency",
                        "html": "Urinary urgency"
                    },
                    {
                        "textContent": "Urinary incontinence",
                        "html": "Urinary incontinence"
                    },
                    {
                        "textContent": "Neurogenic bladder instability",
                        "html": "Neurogenic bladder instability"
                    }
                ],
                "specificity": {
                    "routes": [
                        "transdermal application using patches"
                    ],
                    "textContent": "By transdermal application using patches",
                    "html": "By transdermal application using patches"
                },
                "child": [
                    {
                        "textContent": "Initially 2.5&#8211;3 mg twice daily, (by mouth using immediate-release medicines) increased to 5 mg 2&#8211;3 times a day.",
                        "html": "<p>Initially 2.5&#8211;3&#8239;mg twice daily, (by mouth using immediate-release medicines) increased to 5&#8239;mg 2&#8211;3 times a day.</p>",
                        "ageGroup": "5&#8211;11 years"
                    },
                    {
                        "textContent": "Initially 5 mg 2&#8211;3 times a day, (by mouth) increased if necessary up to 5 mg 4 times a day.",
                        "html": "<p>Initially 5&#8239;mg 2&#8211;3 times a day, (by mouth) increased if necessary up to 5&#8239;mg 4 times a day.</p>",
                        "ageGroup": "12&#8211;17 years"
                    },
                    {
                        "textContent": "Initially 5 mg once daily, (by mouth) adjusted in steps of 5 mg every 1 week, adjusted according to response; maximum 15 mg per day.",
                        "html": "<p>Initially 5&#8239;mg once daily, (by mouth) adjusted in steps of 5&#8239;mg every 1&#8239;week, adjusted according to response; maximum 15&#8239;mg per day.</p>",
                        "ageGroup": "5&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "Initially 5 mg 2&#8211;3 times a day, (by mouth) increased if necessary up to 5 mg 4 times a day.",
                        "html": "<p>Initially 5&#8239;mg 2&#8211;3 times a day, (by mouth) increased if necessary up to 5&#8239;mg 4 times a day.</p>"
                    },
                    {
                        "textContent": "Initially 2.5&#8211;3 mg twice daily, (by mouth using immediate-release medicines) increased if tolerated to 5 mg twice daily, adjusted according to response.",
                        "html": "<p>Initially 2.5&#8211;3&#8239;mg twice daily, (by mouth using immediate-release medicines) increased if tolerated to 5&#8239;mg twice daily, adjusted according to response.</p>",
                        "ageGroup": "elderly"
                    },
                    {
                        "textContent": "Initially 5 mg once daily, (by mouth) increased in steps of 5 mg every 1 week, adjusted according to response; maximum 20 mg per day.",
                        "html": "<p>Initially 5&#8239;mg once daily, (by mouth) increased in steps of 5&#8239;mg every 1&#8239;week, adjusted according to response; maximum 20&#8239;mg per day.</p>"
                    },
                    {
                        "textContent": "Apply 1 patch twice weekly, patch is to be applied to clean, dry unbroken skin on abdomen, hip or buttock. Patch should be removed every 3-4 days and site replacement patch on a different area. The same area should be avoided for 7 days.",
                        "html": "<p>Apply 1&#8239;patch twice weekly, patch is to be applied to clean, dry unbroken skin on abdomen, hip or buttock. Patch should be removed every 3-4 days and site replacement patch on a different area. The same area should be avoided for 7 days.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Nocturnal enuresis associated with overactive bladder",
                        "html": "Nocturnal enuresis associated with overactive bladder"
                    }
                ],
                "specificity": {
                    "routes": [
                        "Initially mouth using modified-release tablets"
                    ],
                    "textContent": "Initially by mouth using modified-release tablets",
                    "html": "Initially by mouth using modified-release tablets"
                },
                "child": [
                    {
                        "textContent": "2.5&#8211;3 mg twice daily, increased to 5 mg 2&#8211;3 times a day, last dose to be taken before bedtime.",
                        "html": "<p>2.5&#8211;3&#8239;mg twice daily, increased to 5&#8239;mg 2&#8211;3 times a day, last dose to be taken before bedtime.</p>",
                        "ageGroup": "5&#8211;17 years"
                    },
                    {
                        "textContent": "Initially 5 mg once daily, (by mouth) adjusted in steps of 5 mg every 1 week, adjusted according to response; maximum 15 mg per day.",
                        "html": "<p>Initially 5&#8239;mg once daily, (by mouth) adjusted in steps of 5&#8239;mg every 1&#8239;week, adjusted according to response; maximum 15&#8239;mg per day.</p>",
                        "ageGroup": "5&#8211;17 years"
                    }
                ]
            }
        ],
        "doseEquivalence": [
            {
                "type": "doseEquivalence",
                "title": "Dose equivalence and conversion",
                "textContent": "Patients taking immediate-release oxybutynin may be transferred to the nearest equivalent daily dose of Lyrinel XL",
                "html": "<p>Patients taking immediate-release oxybutynin may be transferred to the nearest equivalent daily dose of <i>Lyrinel <tm tmtype=\"reg\"/> XL</i>\n</p>"
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "textContent": "Not licensed for use in children under 5 years.\n\nIntravesical instillation not licensed for use in children.",
                "html": "<p>Not licensed for use in children under 5 years.</p><p>Intravesical instillation not licensed for use in children.</p>"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Acute porphyrias",
                "html": "<xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>",
                "references": [
                    {
                        "id": "PHP78608",
                        "label": "Acute porphyrias"
                    }
                ]
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Anorexia",
                        "html": "Anorexia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "facial flushing",
                        "html": "facial flushing",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Night terrors",
                        "html": "Night terrors",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Cognitive impairment in adults",
                        "html": "Cognitive impairment in adults",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known",
                            "patientType": "adults"
                        }
                    }
                ]
            }
        },
        "specific": {
            "frequencies": {
                "rare": [
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "application site reactions with patches in adults",
                        "html": "application site reactions with <i>patches</i> in adults",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "With transdermal use",
                            "html": "With transdermal use",
                            "routes": [
                                "transdermal"
                            ],
                            "patientType": "adults"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturers advise avoid unless essential&#8212;toxicity in animal studies.",
                "html": "<p>Manufacturers advise avoid unless essential&#8212;toxicity in <i>animal</i> studies.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturers advise avoid&#8212;present in milk in animal studies.",
                "html": "<p>Manufacturers advise avoid&#8212;present in milk in <i>animal</i> studies.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution.",
                "html": "<p>Manufacturer advises caution.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution.",
                "html": "<p>Manufacturer advises caution.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With transdermal use in adults",
                    "html": "With <ph outputclass=\"route\">transdermal</ph> use in adults",
                    "patientType": "adults",
                    "routes": [
                        "transdermal"
                    ]
                },
                "textContent": "Apply patches to clean, dry, unbroken skin on abdomen, hip or buttock, remove after every 3&#8211;4 days and site replacement patch on a different area (avoid using same area for 7 days).",
                "html": "<p>Apply patches to clean, dry, unbroken skin on abdomen, hip or buttock, remove after every 3&#8211;4 days and site replacement patch on a different area (avoid using same area for 7 days).</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "specificity": {
                    "textContent": "In adults",
                    "html": "In adults",
                    "patientType": "adults"
                },
                "textContent": "The need for continuing therapy for urinary incontinence should be reviewed every 4&#8211;6 weeks until symptoms stabilise, and then every 6&#8211;12 months.",
                "html": "<p>The need for continuing therapy for urinary incontinence should be reviewed every 4&#8211;6 weeks until symptoms stabilise, and then every 6&#8211;12 months.</p>"
            },
            {
                "type": "prescribingAndDispensingInformation",
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "textContent": "The need for therapy for urinary indications should be reviewed soon after it has been commenced and then at regular intervals; a response usually occurs within 6 months but may take longer.",
                "html": "<p>The need for therapy for urinary indications should be reviewed soon after it has been commenced and then at regular intervals; a response usually occurs within 6 months but may take longer.</p>"
            },
            {
                "type": "prescribingAndDispensingInformation",
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "textContent": "Intravesical instillation may be available from 'special-order' manufacturers or specialist importing companies.",
                "html": "<p>Intravesical instillation may be available from 'special-order' manufacturers or specialist importing companies.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "patientResources": [
            {
                "type": "patientResources",
                "references": [
                    {
                        "id": "http://www.medicinesforchildren.org.uk/oxybutynin-for-daytime-urinary-symptoms",
                        "label": "www.medicinesforchildren.org.uk/oxybutynin-for-daytime-urinary-symptoms"
                    }
                ],
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "title": "Medicines for Children leaflet: Oxybutynin for daytime urinary symptoms",
                "textContent": "www.medicinesforchildren.org.uk/oxybutynin-for-daytime-urinary-symptoms",
                "html": "<p>\n<xref format=\"html\" href=\"http://www.medicinesforchildren.org.uk/oxybutynin-for-daytime-urinary-symptoms\">www.medicinesforchildren.org.uk/oxybutynin-for-daytime-urinary-symptoms</xref>\n</p>"
            }
        ],
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "specificity": {
                    "textContent": "With transdermal use in adults",
                    "html": "With <ph outputclass=\"route\">transdermal</ph> use in adults",
                    "patientType": "adults",
                    "routes": [
                        "transdermal"
                    ]
                },
                "textContent": "Patients or carers should be given advice on how to administer oxybutynin transdermal patches.",
                "html": "<p>Patients or carers should be given advice on how to administer oxybutynin transdermal patches.</p>"
            }
        ]
    },
    "nationalFunding": {
        "smcDecisions": [
            {
                "type": "smcDecisions",
                "textContent": "With transdermal use in adults The Scottish Medicines Consortium has advised (July 2005) that Kentera should be restricted for use in patients who benefit from oral oxybutynin but cannot tolerate its side-effects.",
                "html": "<p outputclass=\"specificity\">With <ph outputclass=\"route\">transdermal</ph> use in adults</p> <p>The <i>Scottish Medicines Consortium</i> has advised (July 2005) that <i>Kentera</i> <tm tmtype=\"reg\"/> should be restricted for use in patients who benefit from oral oxybutynin but cannot tolerate its side-effects.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral suspension",
                "oral solution",
                "bladder irrigation"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77041",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77048",
                "label": "Modified-release tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77063",
                "label": "Oral solution",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77056",
                "label": "Transdermal patch",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78573",
                "label": "Urinary frequency, enuresis and incontinence",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_356",
                "label": "Oxybutynin",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34659",
                "label": "ANTIMUSCARINICS (SYSTEMIC)",
                "type": "drugClass"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78608",
                "label": "Acute porphyrias",
                "type": "treatmentSummary"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77041",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77048",
                "label": "Modified-release tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77063",
                "label": "Oral solution",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77056",
                "label": "Transdermal patch",
                "type": "medicinalForm"
            }
        ]
    }
}